Evolent Health Files 8-K

Ticker: EVH · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1628908

Evolent Health, INC. 8-K Filing Summary
FieldDetail
CompanyEvolent Health, INC. (EVH)
Form Type8-K
Filed DateJun 4, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $25 m, $7 million
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials, sec-filing

Related Tickers: EVH

TL;DR

EVH filed an 8-K on June 4th covering Reg FD, other events, and financials.

AI Summary

Evolent Health, Inc. filed an 8-K on June 4, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Arlington, Virginia.

Why It Matters

This 8-K filing provides updates and disclosures from Evolent Health, Inc. to the SEC, which are important for investors to understand the company's current status and any material events.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting routine events and disclosures, not indicating any immediate or significant risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves to report on Regulation FD disclosures, other events, and financial statements and exhibits for Evolent Health, Inc.

When was this 8-K report filed?

The 8-K report was filed on June 4, 2024.

What is the exact name of the company filing this report?

The exact name of the registrant is Evolent Health, Inc.

Where are Evolent Health, Inc.'s principal executive offices located?

Evolent Health, Inc.'s principal executive offices are located at 1812 N. Moore Street, Suite 1705, Arlington, Virginia, 22209.

What is the Commission File Number for Evolent Health, Inc.?

The Commission File Number for Evolent Health, Inc. is 001-37415.

Filing Stats: 801 words · 3 min read · ~3 pages · Grade level 10.1 · Accepted 2024-06-04 07:05:11

Key Financial Figures

Filing Documents

01 - Regulation FD Disclosure

Item 7.01 - Regulation FD Disclosure. Attached as Exhibit 99.1 and incorporated by reference herein is a press release dated June 4, 2024 issued by Evolent Health, Inc. (the "Company"), announcing the transaction described in Item 8.01 below. Attached as Exhibit 99.2 and incorporated by reference herein is an investor presentation dated June 4, 2024, which will be presented at the 44th Annual William Blair Stock Growth Conference and has been posted to the investor relations section of the Company's website. The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject the Company or any other person to liability under that Section, and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing.

01 - Other Events

Item 8.01 - Other Events. On June 4, 2024, the Company announced that it had entered into an agreement to acquire certain assets from Machinify and a perpetual, royalty-free license of Machinify Auth for cash consideration of $25 million, plus an earn-out of up to $7 million. The acquisition is subject to customary closing conditions and is expected to close in the third quarter of 2024.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the "PSLRA"), including with respect to the timing and expected benefits of the Machinify acquisition. The Company claims the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA. Actual events or results may differ materially from those contained in these forward-looking statements. In addition, please refer to the periodic reports that the Company has filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023. Such filings by the Company identify and address other important factors that could cause future events or results to vary from the forward-looking statements set forth in this Current Report on Form 8-K. The Company disclaims any obligation to update any forward-looking statements contained herein to reflect events or circumstances that occur after the date hereof.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Evolent Health, Inc., dated June 4 , 2024. 99.2 Investor Presentation, dated June 4, 2024. 104 The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 4, 2024 EVOLENT HEALTH, INC. By: /s/ Jonathan Weinberg Name: Jonathan Weinberg Title: General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing